Dr Sehn presents at a press conference at ASCO 2015 about a phase III study finds that adding the new anti-CD20 monoclonal antibody obinutuzumab to standard bendamustine chemotherapy significantly delays progression of indolent non-Hodgkin lymphoma (NHL).
Read the news article for more.